Genetico's loss under RAS for 3 months of 2026 amounted to ₽23.2 million, up 11% from ₽20.9 million in the previous year. Revenue decreased by 24.3% to ₽101.6 million against ₽134.2 million a year earlier.

Genetico's loss under RAS for 2025 amounted to ₽66.07 million, increasing fivefold compared to ₽13.29 million in the previous year. Revenue increased by 29.8% to ₽553 million against ₽426 million a year earlier.

Genetico has registered 34 patents for its developments related to preimplantation genetic diagnosis. Another 28 patent applications are currently under review. Genetico's solutions are used in the IVF protocol, including under the compulsory health insurance system, and allow for the early detection of high-risk genetic disorders, even before the embryo is...

Genetico is investing 50 million rubles in the startup Cardiogenex, which develops gene therapy drugs for the treatment of hereditary heart diseases. Startup uses the funds received to validate models of cardiomyopathic diseases, conduct animal studies to select the most effective candidate drugs for preclinical research. There are about 730,000 people with...